Phase I/II TRANSCEND CLL 004: Lisocabtagene Maraleucel (JCAR017) in R/R CLL/SLL After BTK Inhibition Failure

May 31 - June 4, 2019; Chicago, Illinois
In patients with R/R CLL previously treated with ibrutinib, use of the CD19-directed CAR T-cell therapy lisocabtagene maraleucel was associated a high response rate and undetectable MRD along with low rates of grade ≥ 3 CRS and neurologic events.
Format: Microsoft PowerPoint (.ppt)
File Size: 205 KB
Released: June 7, 2019


Provided by the USF Health

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Celgene Corporation

Related Content

Drs David Kuter and Catherine M. Broome review the latest available clinical data for emerging therapy options for ITP, from Clinical Care Options (CCO)

person default Catherine M. Broome, MD David J. Kuter, MD, DPhil Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 5, 2021 Expired: August 4, 2022

From Clinical Care Options (CCO), Caron Jacobson, MD, discusses best practices in managing delayed toxicities associated with CAR T-cell therapy

person default Caron A. Jacobson, MD Released: August 5, 2021

From Clinical Care Options (CCO), download slides reviewing key CAR T-cell therapy considerations for managed care and specialty pharmacy professionals

person default Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Released: August 4, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.